2.50%
-3.34%
-2.30%
9.94%
-20.25%
13.67%
13.67%
AI Spotlight on ALVO
Company Description
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide.It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer.The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass.
It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product.The company was founded in 2013 and is headquartered in Reykjavik, Iceland.
Market Data
| Last Price | 12.72 |
| Change Percentage | 2.50% |
| Open | 12.8 |
| Previous Close | 12.41 |
| Market Cap ( Millions) | 3835 |
| Volume | 819899 |
| Year High | 18 |
| Year Low | 9.15 |
| M A 50 | 12.46 |
| M A 200 | 12.51 |
Financial Ratios
| FCF Yield | -7.85% |
| Dividend Yield | 0.00% |
| ROE | 69.49% |
| Debt / Equity | -343.46% |
| Net Debt / EBIDTA | -2048.03% |
| Price To Book | -9.77 |
| Price Earnings Ratio | -7.61 |
| Price To FCF | -12.73 |
| Price To sales | 10.44 |
| EV / EBITDA | -94.42 |
News
- Jan -27 - Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)
- Jan -27 - Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)
- Jan -15 - Has Alvotech (ALVO) Outpaced Other Medical Stocks This Year?
- Dec -30 - Are Medical Stocks Lagging Alvotech (ALVO) This Year?
- Dec -23 - Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024
- Dec -23 - Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024
- Dec -16 - Wall Street Analysts Believe Alvotech (ALVO) Could Rally 39.83%: Here's is How to Trade
- Dec -12 - Is Alvotech (ALVO) Stock Outpacing Its Medical Peers This Year?
- Nov -21 - Alvotech's Position In The Coming Biosimilar Gold Rush
- Nov -14 - Alvotech (ALVO) Q3 2024 Earnings Call Transcript
- Nov -14 - Alvotech (ALVO) Q3 Earnings and Revenues Beat Estimates
- Nov -07 - Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore's HealthCONx Conference on December 5, 2024
- Nov -07 - Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore's HealthCONx Conference on December 5, 2024
- Nov -04 - European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)
- Oct -25 - Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024
- Oct -25 - Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024
- Oct -22 - Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
- Oct -22 - Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
- Oct -10 - European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
- Oct -10 - European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Biosimilar Medicines
Expected Growth : 11.6 %
What the company do ?
Alvotech's biosimilar medicines are high-quality, affordable copies of original biologics, offering patients and healthcare systems cost-effective alternatives for treating chronic diseases.
Why we expect these perspectives ?
Alvotech's 11.6% growth in biosimilar medicines is driven by increasing demand for cost-effective alternatives to biologics, patent expirations of originator products, and growing adoption in emerging markets. Additionally, Alvotech's strong pipeline, strategic partnerships, and expanding global footprint are contributing to its rapid growth.
Alvotech Products
| Product Range | What is it ? |
|---|---|
| Biosimilar medicines | Alvotech develops and manufactures biosimilar medicines, which are highly similar to existing biologics, offering a more affordable treatment option for patients. |
| Autoimmune disease treatments | Alvotech's pipeline includes biosimilars for autoimmune diseases, aiming to improve treatment outcomes and patient quality of life. |
| Oncology treatments | Alvotech develops biosimilars for cancer treatment, providing a cost-effective alternative to existing biologics. |
| Ophthalmology treatments | Alvotech's pipeline includes biosimilars for ophthalmology, focusing on treatments for age-related macular degeneration and other eye diseases. |
| Inflammatory bowel disease treatments | Alvotech develops biosimilars for inflammatory bowel disease, aiming to improve treatment outcomes and patient quality of life. |
Alvotech's Porter Forces
Threat Of Substitutes
Alvotech's biosimilar products may face competition from other biosimilar manufacturers, but the company's strong R&D capabilities and partnerships with major pharmaceutical companies mitigate this threat.
Bargaining Power Of Customers
Alvotech's customers, primarily pharmaceutical companies, have limited bargaining power due to the company's unique biosimilar products and strong partnerships.
Bargaining Power Of Suppliers
Alvotech relies on a few key suppliers for raw materials and manufacturing services, but the company's strong relationships and diversified supply chain mitigate the bargaining power of suppliers.
Threat Of New Entrants
The biosimilar industry has high barriers to entry, including significant R&D investments and regulatory hurdles, making it difficult for new entrants to compete with Alvotech.
Intensity Of Rivalry
The biosimilar industry is highly competitive, with several established players competing for market share, but Alvotech's strong product pipeline and partnerships position the company for success.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 752.18% |
| Debt Cost | 3.95% |
| Equity Weight | -652.18% |
| Equity Cost | 3.84% |
| WACC | 4.66% |
| Leverage | -115.33% |
Alvotech : Quality Control
Alvotech passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| DMP.DE | Dermapharm Holding SE, together with its subsidiaries, engages in the off-patent branded pharmaceuticals business in Germany and internationally. It operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel … |
| PRGO | Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. The company operates through … |
| ALM.MC | Almirall, S.A., a biopharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines in Europe, the United States, and internationally. The company offers its products for … |
| SOBI.ST | Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North … |
| SFZN.SW | Siegfried Holding AG engages in the life sciences business worldwide. The company develops and produces active pharmaceutical ingredients (APIs) and intermediates, as well as finished dosage forms, including solid oral … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Dermapharm Holding
A-Score
1-Year Total Return ->
🥈
Almirall
A-Score
1-Year Total Return ->
🥉
Siegfried Holding
A-Score
1-Year Total Return ->
4
Sobi
A-Score
1-Year Total Return ->
5
Alvotech
A-Score
1-Year Total Return ->
6
